Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan

References

• Food and Drug Administration. FDA approves first biosimilar for treatment of adult patients with non-Hodgkin’s lymphoma. [cited 2022 Oct 27]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treatment-adult-patients-non-hodgkins-lymphoma.
   Google Scholar
• Seyfizadeh N, Seyfizadeh N, Hasenkamp J, et al. A molecular perspective on rituximab: a monoclonal antibody for B cell non hodgkin lymphoma and other affections. Crit Rev Oncol Hematol. 2016;97:275–290. doi: 10.1016/j.critrevonc.2015.09.001.
   PubMed Web of Science ®Google Scholar
• Aapro M, Cornes P, Sun D, et al. Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer. Ther Adv Med Oncol. 2012;4(3):95–105. doi: 10.1177/1758834012444499.
   PubMed Web of Science ®Google Scholar
• Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract. 2012;18(2):171–179. doi: 10.1177/1078155211407367.
   PubMedGoogle Scholar
• Abraham I, Han L, Sun D, et al. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries. Future Oncol. 2014;10(9):1599–1609. doi: 10.2217/fon.14.43.
   PubMed Web of Science ®Google Scholar
• Sun D, Andayani TM, Altyar A, et al. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European union G5 countries: a simulation study. Clin Ther. 2015;37(4):842–857. doi: 10.1016/j.clinthera.2015.01.011.
   PubMed Web of Science ®Google Scholar
• McBride A, Campbell K, Bikkina M, et al. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ. 2017;20(10):1083–1093. doi: 10.1080/13696998.2017.1358173.
   PubMed Web of Science ®Google Scholar
• McBride A, Balu S, Campbell K, et al. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. Future Oncol. 2017;13(25):2285–2295. doi: 10.2217/fon-2017-0374.
   PubMed Web of Science ®Google Scholar
• McBride A, Campbell K, Bikkina M, et al. Reply: cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ. 2018;21(6):606–609. doi: 10.1080/13696998.2018.1452749.
   PubMed Web of Science ®Google Scholar
• McBride A, Krendyukov A, Mathieson N, et al. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-hodgkin lymphoma. J Med Econ. 2020;23(1):28–36. doi: 10.1080/13696998.2019.1658591.
   PubMed Web of Science ®Google Scholar
• McBride A, Wang W, Campbell K, et al. Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim. J Med Econ. 2020;23(8):856–863. doi: 10.1080/13696998.2020.1760284.
   PubMed Web of Science ®Google Scholar
• MacDonald K, McBride A, Alrawashdh N, et al. Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv. J Med Econ. 2020;23(12):1466–1476. doi: 10.1080/13696998.2020.1833339.
   PubMed Web of Science ®Google Scholar
• McBride A, MacDonald K, Abraham I. Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma. Leuk Res. 2021;106:106591. doi: 10.1016/j.leukres.2021.106591.
   PubMed Web of Science ®Google Scholar
• McBride A, MacDonald K, Fuentes-Alburo A, et al. Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer. J Med Econ. 2021;24(1):743–756. doi: 10.1080/13696998.2021.1928515.
   PubMed Web of Science ®Google Scholar
• MacDonald K, Alrawashdh N, McBride A, et al. Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer. Future Oncol. 2021;17(33):4561–4570. doi: 10.2217/fon-2021-0718.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Truxima. [cited 2022 Oct 27]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/truxima.
   Google Scholar
• The World Bank. World Bank country and lending groups. [cited 2022 Oct 27]. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519.
   Google Scholar
• Al-Hajaya S. optimal size of government expenditure in Jordan for the period (1985–2014). Jordan J Econ Sci. 2017;4(2):171–183. doi: 10.12816/0040710.
   Google Scholar
• Alkhatib SM. The contribution of manufactured exports and R&D to industrial growth in Jordan. JJES. 2022;9(1):71–84. doi: 10.35516/jjes.v9i1.252.
   Google Scholar
• Jordan Drug and Food Administration. Pricing of pharmaceuticals. [cited 2022 Oct 27]. Available from: http://www.jfda.jo/Pages/viewpage.aspx?pageID=184.
   Google Scholar
• Abraham I. It’s what we do with the savings: economics and equity. Center for Biosimilars. 2022 [cited 2022 Oct 27]. Available from: https://www.centerforbiosimilars.com/view/dr-ivo-abraham-column-it-s-what-we-do-with-the-savings-economics-and-equity.
   Google Scholar
• Joint Procurement Department. [cited 2022 Oct 27]. Available from: https://portal.jordan.gov.jo/wps/wcm/connect/gov/eGov/Government+Ministries+_+Entities/Joint+Procurement+Department/.
   Google Scholar
• Alkhatib NS, Almutairi AR, Alkhezi OS, et al. Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective. Saudi Pharm J. 2022;30(4):433–439. doi: 10.1016/j.jsps.2022.01.018.
   PubMed Web of Science ®Google Scholar
• Kurki P, Kang HN, Ekman N, et al. Regulatory evaluation of biosimilars: refinement of principles based on the scientific evidence and clinical experience. BioDrugs. 2022;36(3):359–371. doi: 10.1007/s40259-022-00533-x.
   PubMed Web of Science ®Google Scholar
• Alkhatib NS, Abraham I. The six Delta platform for outcome-based contracting for pharmaceuticals. J Med Econ. 2020;23(11):1209–1214. doi: 10.1080/13696998.2020.1824161.
   PubMed Web of Science ®Google Scholar
• Alkhatib NS, Erstad B, Ramos K, et al. Pricing methods in outcome-based contracting: δ3: reference-based pricing. J Med Econ. 2020;23(11):1230–1236. doi: 10.1080/13696998.2020.1815027.
   PubMed Web of Science ®Google Scholar